2cureX gathered decision makers at New Year’s Reception
Yesterday, January 31, 2019, 2cureX AB ("2cureX") arranged 2cureX New Year’s Reception, an event where the company together with its partners and stakeholders gathered to discuss the coming year and the development of IndiTreat®.
During the event, a panel discussion led by David Munis Zepernick, Head of Communication and Public Affairs at Medicon Valley Alliance, was arranged. In the panel discussion, Ole Thastrup, CEO of 2cureX AB, Henrik Harling, Senior Medical & Scientific Advisor, MD, DMSc, Hans Schambye, Chairman of Dansk Biotek and CEO of Galecto Biotech AB and Mikkel Aabenhus Hemmingsen, editor at MedWatch, participated.
“The fact that we have gathered our partners and stakeholders for discussion has given us valuable input that will be available to us in the continued development of our business. We are now continuing the preparations for the market launch of IndiTreat®” says Ole Thastrup, CEO of 2cureX.
For more information about 2cureX:
|Ole Thastrup, Chief Executive Officer||Maarten van der Linden, Chief Business Officer|
|E-mail: firstname.lastname@example.org||E-mail: email@example.com|
|Telephone: +45 22115399||Telephone: +45 22902469|
Telephone: +46 40 615 14 15
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented and CE-IVD marked test for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® presents the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal, ovarian and pancreatic cancer.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).